51st week of 2011 patent applcation highlights part 36 |
Patent application number | Title | Published |
20110311498 | GENERATION OF PATIENT-SPECIFIC DIFFERENTIATED CELL TYPES BY EPIGENETIC INDUCTION - Disclosure of a mammalian cytoplasmic donor cell line. Disclosure of a patient specific cell line. Disclosure of a method to obtain a mammalian cytoplasmic donor cell line by fusing a differentiated mammalian cell and a functionally enucleated mammalian embryonic cell line. Disclosure of a method to obtain a patient specific cell line of a cell type similar to a mammalian cytoplasmic donor cell line by functionally enucleating the mammalian cytoplasmic donor cell line and fusing the functionally enucleated mammalian cytoplasmic donor cell line with a differentiated cell obtained from the patient. A method of treatment administering the patient-specific cell line to the patient. | 2011-12-22 |
20110311499 | Secretion System and Methods for its Use - The present invention provides reagents and methods for inhibiting bacterial infection and abnormal cell growth, as well as for selection cloning of nucleic acid inserts. | 2011-12-22 |
20110311500 | COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS - Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity. | 2011-12-22 |
20110311501 | ANTI-OBESITY AGENT AND ANTI-OBESITY FOOD - An anti-obesity agent containing, as an active ingredient, a microorganism which belongs to the species | 2011-12-22 |
20110311502 | AGENT FOR PREVENTION OR AMELIORATION OF OBESITY - To provide a pharmaceutical product or food which has an excellent fat-accumulation-inhibiting activity and/or fat-metabolism-improving activity and which is effective for inhibition or improvement of obesity, fatty liver, etc. | 2011-12-22 |
20110311503 | Active ingredient combinations having insecticidal and acaricidal properties - The novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) are very suitable for control of animal pests such as insects and/or unwanted acarids. | 2011-12-22 |
20110311504 | COENZYME Q10-CONTAINING COMPOSITION FOR ORAL INGESTION - Disclosed are: a coenzyme Q10 composition for oral ingestion which improves the bioabsorbability of coenzyme Q10 and enables efficient ingestion of coenzyme Q10 and which is highly safe, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion. Combining coenzyme Q10 and a seed processed product has made it possible to provide a coenzyme Q10-containing composition for oral ingestion excellent in bioabsorbability, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion. | 2011-12-22 |
20110311505 | Photosensitive Aminoacid-Monomer Linkage and Bioconjugation Applications in Life Sciences and Biotechnology - This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously enable (i) both purification and determination, (ii) both targeting and imaging and theranostics and (iii) catalysis and determination. The construction and method of preparation is applicable to silica materials, superparamagnetic particles, QDs, CNTs, Ag/Au nanoparticles and Au surfaces and polymeric materials. The photosensitive aminoacid monomer linkers can react via chemically and biocompatible to a lot of different micro and nano-surface and then to the protein when they act as a single-step cross-linking reaction using irradiation. The photosensitive conjugation based on click biochemistry can be carried out at mild conditions, independent of pH and temperature, without affecting conformation and function of protein. | 2011-12-22 |
20110311506 | PIGGYBAC TRANSPOSON VARIANTS AND METHODS OF USE - The present invention provides hyperactive piggyBac transposons, in particular hyperactive piggyBac transposons from | 2011-12-22 |
20110311507 | Methods for Diagnosing and Treating Autoimmune Disorders - Provided herein are, inter alia, methods of identifying patients who are at risk of developing an autoimmune disorder, and treating patients suffering from autoimmune disorders. | 2011-12-22 |
20110311508 | METHOD OF MODULATING HSF-1 - The present invention is directed to methods of modulating HSF1 activity comprising modifying the acetylation of the DNA binding domain of the HSF1. | 2011-12-22 |
20110311509 | TREATMENT OF OCULAR DISEASES - The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of ocular diseases related to neoangiogenesis selected from the group consisting of age related macular degeneration (AMD), choroidal neovascularisation, Hippel-Lindau Disease, iris neovascularisation, ischemic proliferative retinopathy, neovascularisation of the Cornea, and proliferative sickle cell retinopathy, wherein the at least one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases. | 2011-12-22 |
20110311510 | Compositions and methods for prion decontamination - The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents. | 2011-12-22 |
20110311511 | CRYSTAL STRUCTURE OF PfA-M1 AND THE PfA-M1 Co4 COMPLEX - The invention relates to the X-ray crystal structure of PfA-M1 aminopeptidase alone, and in complex with the phosphinate dipeptide analogue hPheP[CH | 2011-12-22 |
20110311512 | Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets - Compositions and methods for the detection and treatment of neurological disorders, including ASD, are provided. | 2011-12-22 |
20110311513 | Methods for treating coagulation disorders - The invention is directed to methods for treating coagulation disorders, in particular, hemophilia. Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents and/or treatment modalities. | 2011-12-22 |
20110311514 | Methods for treating disorders of amino acid metabolism - The invention is directed to methods for treating disorders of amino acid metabolism, in particular, maple sugar urine disease (MSUD). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents and/or treatment modalities. | 2011-12-22 |
20110311515 | PULMONARY ADMINISTRATION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND CONSTRUCTS THEREOF - The present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route. | 2011-12-22 |
20110311516 | Chemically Programmed Vaccination - Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound. | 2011-12-22 |
20110311517 | Antibodies and methods for treating estrogen receptor-associated diseases - Provided herein in certain embodiments are antibodies, antibody fragments, pharmaceutical compositions, methods for modulating the functions of estrogen receptor alpha 36, and methods for preventing and/or treating diseases mediated by estrogen receptor alpha 36. | 2011-12-22 |
20110311518 | NOVEL SYNTHETIC AGONISTS OF TLR9 - The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles. | 2011-12-22 |
20110311519 | METHODS OF TREATMENT OF BONE DEGENERATIVE DISEASES - Methods of reducing bone loss and treating degenerative bone diseases such as osteoporosis are disclosed. The methods comprise administration of an agent that inhibits signaling through the IL-17 pathway, such as an antibody or a quinazoline analogue such as halofuginone. | 2011-12-22 |
20110311520 | METHODS FOR TREATMENT OF ALLERGIC ASTHMA - Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described. | 2011-12-22 |
20110311521 | Novel therapy for anxiety - The present invention relates to a method of modulating, treating or effecting prophylaxis of a subject having anxiety or at risk of developing symptoms of anxiety, said method being characterized in that a therapeutically effective amount of a modulator of chondroitin sulphate proteoglycans is administered to said subject. | 2011-12-22 |
20110311522 | MONOCLONAL ANTIBODIES BINDING TO AVIAN INFLUENZA VIRUS SUBTYPE H5 HAEMAGGLUTININ AND USES THEREOF - The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody. | 2011-12-22 |
20110311523 | PLATELET DERIVED GROWTH FACTOR RECEPTOR SUPPORTS CYTOMEGALOVIRUS INFECTIVITY - The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV). | 2011-12-22 |
20110311524 | Inhibitors of Angiopoietin-Like 4 Protein, Combinations, and Their Use - Modulators of angiopoietin-like 4 protein are provided along with methods for their use in the treatment of diseases and pathological conditions. Combinations of ANGPTL4 antagonists and other therapeutics, e.g., anti-cancer agents, and methods of their use in the treatment of mammals susceptible to or diagnosed with cancer, or with relapse tumor growth or relapse cancer cell growth are also provided. | 2011-12-22 |
20110311525 | DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECT - The invention relates to the use of a CD40 agonist for treating cancer, a pre-malignant disorder or an infectious disease, wherein a CD40 agonist is locally administered and targeted to a tumor draining lymph node of a subject. Optionally, a CD40 agonist is formulated in a slow-release formulation. Optionally, a CTL-activating peptide is further administered. | 2011-12-22 |
20110311526 | POLYNUCLEOTIDE AND POLYPEPTIDE SEQUENCES INVOLVED IN THE PROCESS OF BONE REMODELING - This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides, polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes. | 2011-12-22 |
20110311527 | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS - Disclosed herein is a method of treating certain ocular and other diseases with an anti-IL-23p19 antibody. | 2011-12-22 |
20110311528 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF PSORIASIS - The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, psoriasis. | 2011-12-22 |
20110311529 | METHOD FOR TREATING A RHEUMATIC DISEASE USING A SOLUBLE TLA4 MOLECULE - The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands. | 2011-12-22 |
20110311530 | TRUNCATED BAFF RECEPTORS - The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders. | 2011-12-22 |
20110311531 | IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS - Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies. | 2011-12-22 |
20110311532 | INHIBITION OF COMPLEMENT AND CELLULAR ACTIVATION - A method of inhibiting Fc mediated platelet activation in a subject induced by administration of a therapeutic antibody or fragment thereof includes administering to the subject an amount of anti-platelet agent effective to inhibit Fc induced platelet activation in the subject. | 2011-12-22 |
20110311533 | REGULATION OF PROTEIN LEVEL - The invention relates to regulating the level of a membrane-anchored target molecule using PrP or a fragment thereof and a polyanion. Direct or indirect methods for targeting protein downregulation, mediated through PrP or a fragment thereof and a polyanionare are described. | 2011-12-22 |
20110311534 | WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer. | 2011-12-22 |
20110311535 | NKG2D-FC FOR IMMUNOTHERAPY - Methods for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising an NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands. | 2011-12-22 |
20110311536 | PREVENTION OF TYPE 1 DIABETES BY TREG VACCINATION WITH AN INSULIN MIMETOPE - The invention involves methods and products for inducing Treg cells for immune suppression in connection with autoimmune disease and transplant rejection. | 2011-12-22 |
20110311537 | METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF) - Methods of treating, inhibiting, or ameliorating Familial Mediterranean Fever (FMF) by administering to a subject in need thereof a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, are provided. The IL-1 antagonist can be an antibody or derivative thereof, which is capable of blocking or inhibiting the biological action of IL-1, thereby treating, inhibiting or ameliorating FMF. Also provided are methods of treating, inhibiting, or ameliorating FMF by administering a therapeutically effective amount of an IL-1 antagonist in combination with additional therapeutic agents, including IL-1-specific fusion proteins, TNF inhibitors, NSAIDs, steroids, and the like. | 2011-12-22 |
20110311538 | INHIBITORS OF RECEPTOR TYROSINE KINASES AND METHODS OF USE THEREOF - The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase. | 2011-12-22 |
20110311539 | DIAGNOSIS AND TREATMENT OF CANCER USING CANCER-TESTIS ANTIGENS - The invention relates to CT polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates to the discovery of a novel cancer/testis (CT) antigens CT1.1 (CTSP-5), CT1.11 (CTSP-6), CT1.19 (CTSP-7), CT1.26 (CTSP-8), and CT1.29 (CTSP-9). | 2011-12-22 |
20110311540 | WISP POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME - Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides. | 2011-12-22 |
20110311541 | MUTANT PROTEINS OF THE F PROTEIN OF PIV-5 AND PIV-2 - The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications. | 2011-12-22 |
20110311542 | Sp35 Antibodies and Uses Thereof - Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody | 2011-12-22 |
20110311543 | Tumor Antigens BFA5 for Prevention and/or Treatment of Cancer - The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer. | 2011-12-22 |
20110311544 | Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells - The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells. | 2011-12-22 |
20110311545 | FAMILY OF PAIN PRODUCING SUBSTANCES AND METHODS TO PRODUCE NOVEL ANALGESIC DRUGS - A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation). | 2011-12-22 |
20110311546 | Angiopoietin-2 specific binding agents - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 2011-12-22 |
20110311547 | Arthritis Treatment - Administration of a monoclonal Ab (mAb) that specifically targets IL-1α is useful to treating articular and extra-articular symptoms of arthritis. | 2011-12-22 |
20110311548 | USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO TREAT ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM - The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists. The invention further provides a method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist. | 2011-12-22 |
20110311549 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2011-12-22 |
20110311550 | AGENTS FOR HCV TREATMENT - Provided are polypeptides, including antibodies and fragments thereof, useful for preventing or treating new or recurring infection of hepatitis C virus, as well as methods of preventing or treating new or recurring hepatitis C viral infection. Also provided are modified E1 and E2 polypeptides. | 2011-12-22 |
20110311551 | ANTIBODIES DIRECTED AGAINST HEPATITIS C VIRUS E1E2 COMPLEX, COMPOSITIONS OF HCV PARTICLES, AND PHARMACEUTICAL COMPOSITIONS - The invention provides new conformational antibodies, and more particular conformational monoclonal antibodies and fragments thereof, that are directed against HCV. Also provided are compositions of particles that are recognized by such antibodies, and pharmaceutical compositions containing these particles. Also described are HCV enveloped subviral particles and purified HCV enveloped complete viral particles, as well as processes for their preparation. | 2011-12-22 |
20110311552 | NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF - Means and methods for the diagnosis, characterization, prognosis and treatment of cancer, specifically targeting cancer stem cells are disclosed Provided is an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth, and a method of treating cancer comprising administering said antibody to a subject. | 2011-12-22 |
20110311553 | Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation - The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation. | 2011-12-22 |
20110311554 | Compositions and Methods for Suppressing Fibrocytes - The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety of applications including treatment and prevention of conditions resulting from fibrosis in the liver, kidney, lung, heart and pericardium, eye, skin, mouth, pancreas, gastrointestinal tract, brain, breast, bone marrow, bone, genitourinary system, a tumor, or a wound. | 2011-12-22 |
20110311555 | Tc11 as a Transcriptional Regulator - Methods and compositions for the diagnosis, prognosis and/or treatment of B cell chronic lymphocytic leukemia associated diseases are disclosed. | 2011-12-22 |
20110311556 | ANTI-RHESUS D MONOCLONAL ANTIBODY - The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4. | 2011-12-22 |
20110311557 | RECIPROCAL SERUM/PLASMA EXCHANGE FOR THE TREATMENT OF CANCER - Techniques for treating cancer are provided. The techniques include obtaining an amount of serum and/or plasma from at least a first patient with a given type of cancer and administering at least a portion of the serum and/or plasma obtained from the first patient to at least a second patient with the same or different type of cancer. Administering the serum and/or plasma obtained from the first patient to the second patient includes administering a therapeutically effective amount of one or more immunoglobulins and one or more soluble receptors corresponding to each immunoglobulin so as to enable reconstitution of a humoral immune system of the second patient to thereby treat the cancer in the second patient. | 2011-12-22 |
20110311558 | Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases - Methods, compositions and kits are disclosed for inhibiting interferon production and modulating immune responses, particularly an autoimmune response. In certain embodiments, the methods involve administering an effective amount of a BST2 protein or a nucleic acid encoding an BST2 protein to treat an autoimmune disease or disorder. | 2011-12-22 |
20110311559 | METHOD OF IDENTIFYING CD4+ CD25+ T-CELLS ACTIVATED TO AN ANTIGEN WHICH EXPRESS CD8 - The invention relates to a method of identifying CD4 | 2011-12-22 |
20110311560 | Methods and Compositions Relating to CCR5 Antagonist, IFN-Gamma and IL-13 Induced Inflammation - The present invention includes compositions and methods for the treatment of Th1 and/or Th2 mediated inflammatory diseases, relating to inhibiting CCR5. This is because the present invention demonstrates, for the first time, that expression of IFN-γ, IL-13, and CCR5, mediates and/or is associated with Th1 and/or Th2 inflammatory diseases and that inhibiting CCR5 treats, and even prevents, the diseases. Thus, the invention relates to the novel discovery that inhibiting CCR5 treats and prevents Th1 and/or Th2 mediated inflammatory disease. | 2011-12-22 |
20110311561 | NON-NATURAL MIC PROTEINS - This invention describes soluble, monovalent, non-natural protein molecules that can activate NK cells and certain T-cells to attack specific cellular target cells by attaching the NKG2D-binding portions of monovalent MICA or MICB protein, i.e. their α1-α2 platform domain, to the intended target cell specifically. The α1-α2 domain is contiguous with a heterologous α3 domain that has been genetically modified to bind directly or indirectly to the extracellular aspect of the target cell, thereby serving as the targeting domain. The genetic modification to create a non-natural and non-terminal targeting motif within the α3 domain can include a portion of an antibody, another protein molecule or portion thereof, a peptide, or a non-natural, modified α3 domain of a MIC protein. | 2011-12-22 |
20110311562 | Glycolipid Mixture with Anti-Inflammatory Activity Obtained from Oscillatoria Planktothrix - It was observed that a highly purified preparation of polar glycolipids extracted from cells of the cyanobacterium | 2011-12-22 |
20110311563 | Synthetic Antigenic Peptides and Lipopeptides Derived from Mycobacterium Avium Subsp. Paratubuerculosis - The current invention relates to the diagnosis and treatment of diseases resulting from infections by | 2011-12-22 |
20110311564 | Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles - The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers. | 2011-12-22 |
20110311565 | Phage Constructs, Sequences and Antigenic Compositions for Immunocontraception of Animals - Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals, which include landscape bacteriophage. The disclosed compositions may include immunogenic compositions or vaccines. | 2011-12-22 |
20110311566 | METHODS AND MATERIALS FOR GENERATING T CELLS - The document provides to methods and materials for generating T cells (e.g., antigen-specific CD4 | 2011-12-22 |
20110311567 | Immunogenically-Enhanced Polypeptides and Related Methods - Described herein are immunogenically-enhanced polypeptides, such as KSHV LANA1 polypeptides, related methods of eliciting an immune response to the polypeptides and related nucleotide sequences. Also described herein are novel polypeptides capable of inhibiting degradation and/or retarding synthesis of a protein when attached to or incorporated within that protein along with related methods and nucleotide sequences. | 2011-12-22 |
20110311568 | Vaccine - The present invention provides a foot and mouth disease (FMD) vaccine comprising or capable of expressing afoot and mouth disease virus (FMDV) VP1 polypeptide having a deletion of at least seven amino acids in the G-H loop such that the VP1 polypeptide lacks an RGD motif. The present invention also provides a method for preventing and/or treating FMD in a subject which comprises the step of administration of such a vaccine. | 2011-12-22 |
20110311569 | HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof - This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against abroad spectrum of HIV-I isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-I. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-I primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-I entry into cells, as well as methods of treatment using the inhibitors. | 2011-12-22 |
20110311570 | PROTEINS WITH REPETITIVE BACTERIAL-IG-LIKE (BIG) DOMAINS PRESENT IN LEPTOSPIRA SPECIES - The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the | 2011-12-22 |
20110311571 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIA USING AN INVASION LIGAND DIRECTED TO A PROTEASE-RESISTANT RECEPTOR - This invention relates to an immunogenic molecule comprising a contiguous amino acid sequence of an invasion ligand of a strain of | 2011-12-22 |
20110311572 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 2011-12-22 |
20110311573 | Method for Preparing Recombinant Antigen Complex Using Rotavirus Nanoparticle - Disclosed are a construct for expressing a rotavirus antigen complex loaded with a heterologous virus epitope, a vaccine composition containing the rotavirus antigen complex, a virus-like particle of rotavirus containing the rotavirus antigen complex, and a vaccine composition containing the virus-like particle of rotavirus. According to the present disclosure, an antigen complex containing a rotavirus antigen as well as a heterologous virus epitope and a virus-like particle of rotavirus containing the antigen complex can be produced in large scale at low cost. Thus, the present disclosure may be applied for research and development of novel complex vaccines for rotavirus and heterologous virus. | 2011-12-22 |
20110311574 | MULTIPLE VACCINATION INCLUDING SEROGROUP C MENINGOCOCCUS - Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular | 2011-12-22 |
20110311575 | MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES - A liquid D-T-Pa component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined vaccine. | 2011-12-22 |
20110311576 | MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH NON-HIB VACCINES - An aqueous immunogen formulation is used to reconstitute a lyophilised component including conjugates of capsular saccharides from | 2011-12-22 |
20110311577 | METHOD OF PRODUCING A VACCINE - The present invention relates to a method for purifying bacterial cytolysins such as pneumococcal pneumolysin. A single chromatography step produces excellent purification of the cytolysin by binding soluble aggregated cytolysin to a hydrophobic interaction chromatography material in the presence of detergent and high salt. | 2011-12-22 |
20110311578 | RECOMBINANT INACTIVATED VIRAL VECTOR VACCINE - A vaccine is described, comprising an inactivated viral vector having inserted an exogenous nucleotide sequence coding for a disease of concern; and, a pharmaceutically acceptable vehicle, adjuvant or excipient, which provides due protection against the disease of concern by using a viral vector titer similar to that required for an active-virus vaccine based on the same viral vector. Mainly, viral vectors of paramixovirus or adenovirus are described. | 2011-12-22 |
20110311579 | Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof - This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery. | 2011-12-22 |
20110311580 | Settings for recombinant adenoviral-based vaccines - Described are new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, also described are new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting. | 2011-12-22 |
20110311581 | REVERSE GENETICS OF NEGATIVE-STRAND RNA VIRUSES IN YEAST - The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA. | 2011-12-22 |
20110311582 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R | 2011-12-22 |
20110311583 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - (A1) Translate this text The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(0)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ?-aminoalkyl, ?-(substituted)aminoalky, ?-phosphoalkyl or ?-thiophosphoalkyl. | 2011-12-22 |
20110311584 | USE OF FLT3 LIGAND FOR ENHANCING IMMUNE RESPONSES IN RNA IMMUNIZATION - The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans). | 2011-12-22 |
20110311585 | Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity - Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity. | 2011-12-22 |
20110311586 | Materials and methods for respiratory disease control in canines - The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention. | 2011-12-22 |
20110311587 | Fusogenic virus-like particles and uses thereof - Provided herein are novel Paramyxovirus virus-like particles, wherein said virus-like particles are composed of surface glycoprotein G; surface glycoprotein F; and matrix protein M. Further provided is a vaccine comprising the virus-like particles described herein and a pharmaceutically acceptable carrier. Also provided is a method of vaccinating a subject against paramyxovirus infection comprising administering the vaccine described herein. | 2011-12-22 |
20110311588 | AGENTS AND TREATMENT FOR SNORING AND RESPIRATORY EFFORT RELATED AROUSALS IN SLEEP - A method for prophylaxis or treatment of respiratory effort related arousals during sleep of a subject is provided. The method comprises administering to the subject an effective amount of an agent for reducing or inhibiting infection or colonisation of the nasal cavity of the subject by | 2011-12-22 |
20110311589 | COMPOSITIONS AND DOSAGE REGIMES COMPRISING A CLOSTRIDIAL VACCINE AND LEVAMISOLE - A composition and dosage regime including a vaccine and levamisole for the treatment of clostridial diseases and helminthiasis. New methods of administration relating to particular dosage regimes of such a composition are also claimed. | 2011-12-22 |
20110311590 | COMPOSITIONS FOR TREATING AN ALLERGIC OR ASTHMATIC CONDITION - Compositions including human Tr1 cells directed to an allergen associated to an allergen or asthmatic provided the allergen is not a food allergen and use thereof for treating an allergic or asthmatic condition, excluding a food allergic condition. | 2011-12-22 |
20110311591 | Antimicrobial Coating - A substrate (100) comprising a sol-gel derived coating (101). The coating, is chemically bonded to the substrate (100) and is derived from a polysiloxane to form a network of silicon-carbon and silicon-oxygen bonds. An antimicrobial is releasably captured within the network and is capable of defusing from the coating in vivo in response to introduction of a fluid into the coating. | 2011-12-22 |
20110311592 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds - The subject invention relates to novel soluble forms of planar ring structured organic compounds including flavonoids, and their production. The invention also includes the use of these novel formulations of planar ring structured organic compounds in the preparation of formulations and products. The invention also relates to a wide variety of applications of the formulations of the invention. The subject invention includes novel soluble forms and various formulations of flavonoids. Further, the invention includes novel methods of manufacturing the flavonoid formulations. The invention also relates to a wide variety of applications of the flavonoid formulations. | 2011-12-22 |
20110311593 | N-HYDROXYLATED AMIDINE-, GUANIDINE- AND/OR AMINOHYDRAZONE-TYPE PRODRUGS FOR APPLICATION ON THE SKIN - The invention relates to N-hydroxylated amidines, guanidines and aminohydrazones for application on the skin. In particular, the invention relates to transdermal therapeutic systems containing N-hydroxylated amidines, guanidines and aminohydrazones as a prodrug, and to methods for producing and using such systems. | 2011-12-22 |
20110311594 | CONTROLLED RELEASE COMPOSITIONS WITH REDUCED FOOD EFFECT - The present invention provides a controlled release pharmaceutical composition which exhibits reduced food effect. | 2011-12-22 |
20110311595 | DOSAGE FORMS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising an effective amount of one or more active ingredients and an effective amount of one or more hydroxypropyl methylcellulose(s), which satisfies the Formula 0.35>ΔH | 2011-12-22 |
20110311596 | POLY(AMIDE) AND POLY(ESTER-AMIDE) POLYMERS AND DRUG DELIVERY PARTICLES AND COATINGS CONTAINING SAME - The current invention relates to poly(amide) and poly(ester-amide) polymers, coatings including the polymers, and narrow polydispersity drug delivery particles including the polymers. | 2011-12-22 |
20110311597 | Magnetically-Oriented Cosmetic Fibers - There is provided a dissolvable film polymer matrix that includes a plurality of magnetically responsive kertin-like fibers for application to an individual's face or head. The dissolvable film polymer matrix product includes hairs that are magnetically oriented in a non-random plain to be applied on an individuals face or head to simulate the appearance of the individual's natural hair. Methods of manufacturing and applying the dissolvable polymer matrix product are also disclosed. | 2011-12-22 |